CR20200347A - Inhibidores pd-1/pd-l1 - Google Patents

Inhibidores pd-1/pd-l1

Info

Publication number
CR20200347A
CR20200347A CR20200347A CR20200347A CR20200347A CR 20200347 A CR20200347 A CR 20200347A CR 20200347 A CR20200347 A CR 20200347A CR 20200347 A CR20200347 A CR 20200347A CR 20200347 A CR20200347 A CR 20200347A
Authority
CR
Costa Rica
Prior art keywords
compounds
inhibitors
cancer
compositions
formula
Prior art date
Application number
CR20200347A
Other languages
English (en)
Inventor
Devan Naduthambi
Michael Graupe
Jonathan William Medley
Scott Preston Simonovich
Kin Shing Yang
Tello Paulo A Machicao
Prasenjit Kumar Mukherjee
Neil H Squires
Christopher Allen Ziebenhaus
Eric Q Parkhill
Lateshkumar Thakorlal Lad
Barton W Phillips
William J Watkins
Zhimin Du
Samuel E Metobo
Evangelos Aktoudianakis
Aesop Cho
Peiyuan Wang
Jie Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65576712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20200347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CR20200347A publication Critical patent/CR20200347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

<p>Se describen compuestos de Fórmula (I), métodos para usar dichos compuestos individualmente o en combinación con agentes y composiciones adicionales de dichos compuestos para el tratamiento del cáncer.</p>
CR20200347A 2018-02-13 2019-02-12 Inhibidores pd-1/pd-l1 CR20200347A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862630187P 2018-02-13 2018-02-13
US201862640534P 2018-03-08 2018-03-08
US201862763116P 2018-04-19 2018-04-19
US201862747029P 2018-10-17 2018-10-17
PCT/US2019/017721 WO2019160882A1 (en) 2018-02-13 2019-02-12 Pd-1/pd-l1 inhibitors

Publications (1)

Publication Number Publication Date
CR20200347A true CR20200347A (es) 2020-09-23

Family

ID=65576712

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200347A CR20200347A (es) 2018-02-13 2019-02-12 Inhibidores pd-1/pd-l1

Country Status (25)

Country Link
US (4) US10710986B2 (es)
EP (2) EP3752501B1 (es)
JP (2) JP7062792B2 (es)
KR (3) KR102708681B1 (es)
CN (2) CN111712494A (es)
AU (3) AU2019222644B2 (es)
BR (2) BR102019002873A2 (es)
CA (1) CA3091015C (es)
CL (1) CL2020002082A1 (es)
CO (1) CO2020009861A2 (es)
CR (1) CR20200347A (es)
DO (1) DOP2020000154A (es)
ES (1) ES2949664T3 (es)
IL (2) IL300572A (es)
MX (2) MX2020008404A (es)
MY (1) MY196582A (es)
PE (1) PE20210640A1 (es)
PH (1) PH12020551244A1 (es)
PL (1) PL3752501T3 (es)
PT (1) PT3752501T (es)
SG (1) SG11202007646UA (es)
SI (1) SI3752501T1 (es)
TW (2) TWI707849B (es)
UA (1) UA126458C2 (es)
WO (1) WO2019160882A1 (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
MA49701A (fr) 2017-07-28 2020-06-03 Chemocentryx Inc Composés immunomodulateurs
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US20210361767A1 (en) 2018-02-14 2021-11-25 Mayo Foundation For Medical Education And Research Rescuing cancer patients from resistance to treatment with inhibitors of pd-1/pd-l1 interactions
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
CA3093851A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020088357A1 (zh) * 2018-11-02 2020-05-07 上海再极医药科技有限公司 联苯类化合物、其中间体、制备方法、药物组合物及应用
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
EP3986392A4 (en) 2019-06-20 2023-07-12 ChemoCentryx, Inc. COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
AU2020357529A1 (en) 2019-09-30 2022-05-19 Medshine Discovery Inc. Compound as small molecule inhibitor PD-1/PD-L1 and application thereof
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CR20220216A (es) * 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
KR102902719B1 (ko) 2019-10-18 2025-12-24 포티 세븐, 엘엘씨 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
US20230029157A1 (en) * 2019-11-26 2023-01-26 The Regents Of The University Of California Combination therapy for head and neck cancer
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
EP4100381A4 (en) * 2020-02-03 2024-04-03 Arbutus Biopharma Corporation SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS OF USE THEREOF
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022022335A2 (pt) 2020-05-05 2023-01-10 Teon Therapeutics Inc Moduladores de receptor canabinoide tipo 2 (cb2) e usos dos mesmos
MX2022016554A (es) * 2020-06-23 2023-04-10 Chemocentryx Inc Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.
JP2023539463A (ja) * 2020-08-17 2023-09-14 アリゴス セラピューティクス インコーポレイテッド Ｐｄ－ｌ１を標的とするための方法及び組成物
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とｃｄ４７遮断の併用
CN112213487B (zh) * 2020-10-23 2021-10-29 郑州大学第一附属医院 Aste1在检测食管鳞癌中的应用
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CN114507227B (zh) * 2020-11-17 2024-06-21 中国医学科学院药物研究所 苯并异噻唑类化合物、及其制法和药物组合物与用途
WO2022147302A1 (en) * 2020-12-30 2022-07-07 Chulalongkorn University 4-phenyl-indole derivatives and related uses
WO2022194908A1 (en) * 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CN113135895A (zh) * 2021-04-30 2021-07-20 中国药科大学 一种新型联苯类衍生物及其制备方法与医药用途
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
US20250057952A1 (en) 2021-05-21 2025-02-20 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
JP7673255B2 (ja) * 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN115677665B (zh) * 2021-07-26 2024-04-19 中国药科大学 含联苯类衍生物及其医药用途
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954B2 (en) 2021-10-29 2026-04-23 Gilead Sciences, Inc. Cd73 compounds
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
CN114085184B (zh) * 2021-11-17 2023-08-29 中山大学 含环丙烷结构的联苯类衍生物及其制备方法和应用
WO2023091932A1 (en) * 2021-11-17 2023-05-25 Cardiff Oncology, Inc. Cancer treatment using lsd1 inhibitors and plk1 inhibitors
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
CA3240346A1 (en) 2021-12-16 2023-06-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022419982B2 (en) 2021-12-22 2026-04-16 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
JP2023132064A (ja) 2022-03-10 2023-09-22 株式会社ジャパンディスプレイ 表示装置及び表示装置の製造方法
EP4493554A1 (en) 2022-03-17 2025-01-22 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
EP4554943A1 (en) 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
TW202412764A (zh) * 2022-08-16 2024-04-01 加拿大商愛彼特生物製藥公司 經取代之１－芳基－１＇－雜芳基化合物及經取代之１，１＇－聯雜芳基化合物及其類似物的合成
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024097741A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
WO2024148209A1 (en) * 2023-01-06 2024-07-11 Staidson Biopharma Inc. Combination of antibodies specifically recognizing tnfr2 and pd-l1 or pd-1
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
KR102841053B1 (ko) * 2023-08-01 2025-08-04 (주)아이랩 Pd-l1 억제제로서 신규한 바이페닐 유도체
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025128264A1 (en) * 2023-12-15 2025-06-19 Pharmaessentia Corporation Anti-pd-1 monoclonal antibody and methods of use thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025199273A1 (en) * 2024-03-22 2025-09-25 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
WO2025210676A1 (en) * 2024-03-30 2025-10-09 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of Elacestrant dihydrochloride and processes for their preparation
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds
WO2026062226A1 (en) * 2024-09-20 2026-03-26 Affirma Biotech S. L. Novel pd-l1 inhibitors
WO2026089992A1 (en) 2024-10-21 2026-04-30 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (511)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
AU712082B2 (en) 1996-02-28 1999-10-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001002661A (ja) 1999-06-22 2001-01-09 Ricoh Co Ltd ニトリル化合物及びその製造方法
JP2001329185A (ja) 1999-06-22 2001-11-27 Ricoh Co Ltd 反応生成物、該反応生成物を用いた電子写真感光体、及び該電子写真感光体を用いた電子写真装置と電子写真装置用プロセスカートリッジ
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2001234689A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Bivalent phenylene inhibitors of factor xa
JP2001335476A (ja) 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU2001288617A1 (en) 2000-09-05 2002-03-22 Neogenesis Pharmaceuticals Inc. Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
US20020115106A1 (en) 2000-12-22 2002-08-22 Neogenesis Pharmaceuticals, Inc. Methods for forming combinatorial libraries using reductive amination
DE10104279A1 (de) 2001-01-31 2002-08-01 Heinz Langhals Kompetitive Prionen-Reagenzien und ihre Anwendung in Diagnostik und Therapie
US6887875B2 (en) 2001-06-12 2005-05-03 Neurogen Corporation 2,5-diarypyrimidine compounds
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003302925A1 (en) 2002-12-11 2004-06-30 Eli Lilly And Company Novel mch receptor antagonists
JP4695395B2 (ja) 2002-12-13 2011-06-08 ニューロジェン・コーポレーション 疼痛治療用の併用療法
US20060293339A1 (en) 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
AU2005220882A1 (en) 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents
JP2007530694A (ja) 2004-03-29 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
CA2583326A1 (en) 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited Receptor function regulating agent
WO2006040646A1 (en) 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
SG170642A1 (en) 2004-11-03 2011-05-30 Arena Pharm Inc Gpr41 and modulators thereof for the treatment of insulin-related disorders
JP2008528590A (ja) 2005-01-28 2008-07-31 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性二環式化合物
US7759493B2 (en) 2005-01-31 2010-07-20 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
EP1951053A4 (en) 2005-10-19 2010-12-01 Merck Sharp & Dohme CETP INHIBITORS
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
EP1953238B1 (en) 2005-11-04 2011-12-21 Eisai R&D Management Co., Ltd. Method for screening of substances using GPR40 and secretory phospholipase A2
US20100249175A1 (en) 2005-12-02 2010-09-30 Wilson W David Dicationic compounds which selectively recognize G-quadruplex DNA
EP1976828B1 (en) 2005-12-29 2016-12-21 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
CN101389963A (zh) 2006-02-22 2009-03-18 菲洛根有限公司 血管性肿瘤标志物
CA2646430A1 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
CN101437536A (zh) 2006-03-23 2009-05-20 诺华有限公司 抗肿瘤细胞抗原抗体治疗
EP2402317B1 (en) 2006-03-31 2013-07-03 Novartis AG DGAT inhibitor
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101421248A (zh) 2006-05-11 2009-04-29 塞诺菲-安万特股份有限公司 4,5-二苯基-嘧啶基取代的羧酸、其生产方法及其作为药物的用途
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE552245T1 (de) 2006-05-15 2012-04-15 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
WO2008037266A1 (en) 2006-09-25 2008-04-03 Universite Libre De Bruxelles Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
WO2008063768A2 (en) 2006-10-12 2008-05-29 Case Western Reserve University Compositions and methods for treating metabolic diseases
WO2008054675A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
US7750048B2 (en) 2006-11-15 2010-07-06 Janssen Pharmaceutica Nv GPR40 agonists
WO2008065409A2 (en) 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
EP2099789A4 (en) 2006-12-04 2012-02-15 Boehringer Ingelheim Int INHIBITORS OF HIV REPLICATION
WO2008073865A2 (en) 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
PT2698062E (pt) 2006-12-28 2015-10-19 Abbvie Inc Inibidores da poli (adp-ribose) polimerase
WO2008090327A1 (en) 2007-01-22 2008-07-31 Betagenon Ab New combination for use in the treatment of cancer
WO2008090356A1 (en) 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
WO2008106202A1 (en) 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
US8486941B2 (en) 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
WO2008147852A1 (en) 2007-05-22 2008-12-04 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
WO2008144925A1 (en) 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2008156656A2 (en) 2007-06-13 2008-12-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for making biaryl compounds, compounds made by the method, and method for their use
EP2002838A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma AG Verwendung von Aryl/Hetarylamid-Derivaten als Modulatoren des EP2-Rezeptors
SI2170888T1 (sl) 2007-06-29 2015-10-30 Gilead Sciences, Inc. Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
TWI600639B (zh) 2007-08-17 2017-10-01 杜邦股份有限公司 製備５-鹵烷基-４，５-二氫異唑衍生物之化合物
WO2009038204A1 (ja) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするｇタンパク質共役型レセプター作動剤
CN101796017A (zh) 2007-09-21 2010-08-04 塞诺菲-安万特股份有限公司 (羧基亚烷基苯基)苯基草酰胺、其生产方法以及作为药物的用途
AU2008303975B2 (en) 2007-09-21 2013-05-16 Sanofi (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
ES2446932T3 (es) 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
ME02338B (me) 2007-10-26 2013-02-28 Japan Tobacco Inc Spiro-ciklično jedinjenje i njegova upotreba u medicinske svrhe
WO2009058237A1 (en) 2007-10-29 2009-05-07 Merck & Co., Inc. Antidiabetic tricyclic compounds
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
ES2524266T3 (es) 2008-07-08 2014-12-04 Incyte Corporation 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
EP3103875A1 (en) 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
WO2010012650A1 (en) 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
CA2739303A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
MX2011006006A (es) 2008-12-08 2011-09-08 Euroscreen Sa Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
EP2380878B1 (en) 2009-01-19 2013-08-14 Daiichi Sankyo Company, Limited Cyclic compound having hetero atom
CA2749930A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
US20110312967A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused antidiabetic compounds
JP2012515779A (ja) 2009-01-23 2012-07-12 シェーリング コーポレイション ペンタフルオロスルホラン含有抗糖尿病化合物
US8575166B2 (en) 2009-02-05 2013-11-05 Merck Sharp & Dohme Corp. Phthalazine-containing antidiabetic compounds
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
ES2606717T3 (es) 2009-02-27 2017-03-27 Enanta Pharmaceuticals, Inc. Inhibidores del virus de la hepatitis C
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
US20120035196A1 (en) 2009-04-22 2012-02-09 Kenji Negoro Carboxylic acid compound
RS56654B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
RU2580320C2 (ru) 2009-08-18 2016-04-10 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
PL2467377T3 (pl) 2009-08-18 2017-10-31 Ventirx Pharmaceuticals Inc Podstawione benzoazepiny jako modulatory receptora toll-podobnego
GB0914856D0 (en) 2009-08-25 2009-09-30 Ark Therapeutics Ltd Compounds
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
CN102639495A (zh) 2009-10-06 2012-08-15 百时美施贵宝公司 吡咯烷gpr40调节剂
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
JPWO2011052756A1 (ja) 2009-10-30 2013-03-21 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
LT2513053T (lt) 2009-12-18 2018-01-25 Ogeda Sa Pirolidino karboksirūgščių dariniai kaip su g baltymu sąveikaujančio receptoriaus 43 (gpr43) agonistai, farmacinės kompozicijos ir būdai, skirti naudoti metabolinių susirgimų gydymui
WO2011076732A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
WO2011076734A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
PH12012501456A1 (en) 2009-12-25 2012-10-29 Mochida Pharm Co Ltd Novel 3-hydroxy -5- arylisothiazole derivative
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011082400A2 (en) * 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US9061012B2 (en) 2010-03-30 2015-06-23 Novartis Ag Uses of DGAT1 inhibitors
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
RU2012154447A (ru) 2010-05-12 2014-06-20 Вандербилт Юниверсити Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2012036168A (ja) 2010-07-15 2012-02-23 Daiichi Sankyo Co Ltd ヘテロ原子を有する環状化合物を含有する医薬組成物
WO2012011124A1 (en) 2010-07-20 2012-01-26 Council Of Scientific & Industrial Research Ordered mesoporous titanosilicate and the process for the preparation thereof
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
SI2608809T1 (sl) 2010-08-27 2019-08-30 Gilead Biologics, Inc. Protitelesa proti matriksu metaloproteinaze 9
JP5850503B2 (ja) 2010-09-14 2016-02-03 北海道公立大学法人 札幌医科大学 筋ジストロフィーを処置するための組成物
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
RU2016118628A (ru) 2010-10-01 2018-11-02 Вентиркс Фармасьютикалз, Инк. Способы лечения аллергических заболеваний
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
EP2640701B1 (en) 2010-11-15 2017-07-05 Bayer Intellectual Property GmbH Cyanoenamines and their use as fungicides
WO2012068234A2 (en) 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
WO2012078802A1 (en) 2010-12-08 2012-06-14 Takeda Pharmaceutical Company Limited PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PY1153144A (es) 2010-12-10 2015-01-01 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae
US20140364616A1 (en) 2010-12-15 2014-12-11 Abbvie Inc. Anti-viral compounds
WO2012083053A2 (en) 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
EP2651928A4 (en) 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
US20150158909A1 (en) 2010-12-15 2015-06-11 Abbevie Inc. Anti-viral compounds
US20150232455A1 (en) 2010-12-15 2015-08-20 Allan C. Krueger Anti-viral compounds
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CA2824779C (en) 2011-01-12 2020-01-14 Array Biopharma, Inc. Substituted benzoazepines as toll-like receptor modulators
ES2620605T3 (es) 2011-01-12 2017-06-29 Ventirx Pharmaceuticals, Inc. Benzoazepinas sustituidas como moduladores de receptores tipo Toll
US8759334B2 (en) 2011-01-19 2014-06-24 Galapagos Nv Compounds useful for the treatment of metabolic and inflammatory diseases
JP5998152B2 (ja) 2011-01-25 2016-09-28 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｂｃｌ−２／ｂｃｌ−ｘｌ阻害剤およびそれを使用する治療方法
EP2672820B1 (en) 2011-02-07 2019-04-17 The Washington University Mannoside compounds and methods of use thereof
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
WO2012111849A1 (en) 2011-02-17 2012-08-23 Takeda Pharmaceutical Company Limited Production method of optically active dihydrobenzofuran derivative
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN104470886A (zh) 2011-04-08 2015-03-25 赛丹思科大学 用于治疗代谢疾病的邻-氟取代的化合物
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
TW201247636A (en) 2011-04-27 2012-12-01 Mochida Pharm Co Ltd Novel 3-hydroxyisothiazole 1-oxide derivatives
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
JP5659189B2 (ja) 2011-05-13 2015-01-28 富士フイルム株式会社 非共鳴２光子吸収材料、非共鳴２光子吸収記録材料、記録媒体、記録再生方法及び非共鳴２光子吸収化合物
SG194852A1 (en) 2011-05-18 2013-12-30 Janssen R & D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
EP2817304A4 (en) 2011-07-14 2015-01-21 Biochromix Newco Ab Novel compounds and their use in therapy
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013027802A1 (ja) 2011-08-23 2013-02-28 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
AU2012318580A1 (en) 2011-10-04 2014-05-22 Gilead Calistoga Llc Novel quinoxaline inhibitors of PI3K
WO2013057743A1 (en) 2011-10-21 2013-04-25 Connexios Life Sciences Pvt. Ltd Process for the preparation of an aryl oxime and salts thereof
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
WO2013102626A1 (en) 2012-01-04 2013-07-11 Sanofi 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament
JP6122871B2 (ja) 2012-01-12 2017-04-26 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． 多環式化合物誘導体、それらの製造方法および医薬用途
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2014008591A (es) 2012-01-16 2014-08-22 Vertex Pharma Piperidinamidas piranoespirociclicas como moduladores de canales de iones.
JP2013147443A (ja) 2012-01-18 2013-08-01 Daiichi Sankyo Co Ltd β置換カルボン酸誘導体
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
JP6283320B2 (ja) 2012-02-08 2018-02-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
EP2816032A4 (en) 2012-02-13 2015-09-30 Takeda Pharmaceutical AROMATIC RING CONNECTION
US9382188B2 (en) 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
TW201341356A (zh) 2012-02-28 2013-10-16 皮拉馬爾企業有限公司 作為gpr促效劑之苯基烷酸衍生物
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013144129A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013154163A1 (ja) 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
WO2013185103A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2013185090A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US20140024708A1 (en) 2012-07-17 2014-01-23 Banavara L. Mylari Ursolic acid salts for treating diabetes and obesity
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX369417B (es) 2012-08-10 2019-11-07 Janssen Sciences Ireland Uc Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades.
KR20200110820A (ko) 2012-08-27 2020-09-25 알레간 인코포레이티드 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후
CN104797561B (zh) 2012-08-28 2017-03-01 爱尔兰詹森科学公司 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途
UY34993A (es) 2012-08-28 2014-02-28 Janssen R & D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2015002954A (es) 2012-09-10 2015-06-05 Hoffmann La Roche Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
US20140073631A1 (en) 2012-09-12 2014-03-13 Vymed Corporation Antiviral and antimicrobial compounds
AR092662A1 (es) 2012-09-24 2015-04-29 Gilead Sciences Inc Anticuerpos anti-ddr1
BR112015007083A2 (pt) 2012-10-02 2017-07-04 Epitherapeutics Aps inibidores de histona demetilases
EA035327B1 (ru) 2012-10-10 2020-05-28 Янссен Сайенсиз Айрлэнд Юси Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
US10034939B2 (en) 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
US20140128333A1 (en) 2012-11-02 2014-05-08 Maqui New Life S.A. Compounds, Compositions, and Methods for Decreasing Intestinal Glucose Uptake and Inducing Incretin Release
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
KR101268466B1 (ko) 2012-11-12 2013-06-04 유병수 사축형 윈드 터빈
BR112015010649A2 (pt) 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina
HUE032401T2 (en) 2012-11-16 2017-09-28 Bristol Myers Squibb Co Dihydropyrazole GPR40 modulators
US9656963B2 (en) 2012-11-16 2017-05-23 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
ES2655843T3 (es) 2012-11-16 2018-02-21 Janssen Sciences Ireland Uc Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas
JP2016501203A (ja) 2012-11-20 2016-01-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
HK1210144A1 (en) 2012-11-28 2016-04-15 勃林格殷格翰国际有限公司 New indanyloxydihydrobenzofuranylacetic acids
CN103848820A (zh) 2012-11-29 2014-06-11 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
HUE037312T2 (hu) 2012-12-19 2018-08-28 Celgene Quanticel Res Inc Hiszton demetiláz inhibitorok
CA2895808A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
TW201441216A (zh) 2012-12-21 2014-11-01 Gilead Calistoga Llc 肌醇磷酯３－激酶的抑制劑
AU2013364070B2 (en) 2012-12-21 2016-10-27 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
WO2014122067A1 (en) 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
MY191389A (en) 2013-02-21 2022-06-22 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014134243A1 (en) 2013-02-27 2014-09-04 Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
PE20151667A1 (es) 2013-02-27 2015-11-27 Epitherapeutics Aps Inhibidores de histona desmetilasas
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
KR101735787B1 (ko) 2013-02-28 2017-05-16 주식회사 티움바이오 삼환식 화합물 및 이의 용도
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
US9133166B2 (en) 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9763905B2 (en) 2013-03-15 2017-09-19 The Children's Medical Center Corporation Therapeutic target for the treatment of cancers and related therapies and methods
RS56561B1 (sr) 2013-03-15 2018-02-28 Quanticel Pharmaceuticals Inc Inhibitori histon demetilaze
CN104059039B (zh) 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
JP6419155B2 (ja) 2013-04-03 2018-11-07 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
CN104109115B (zh) 2013-04-16 2016-11-23 中国科学院上海药物研究所 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
AR096041A1 (es) 2013-04-17 2015-12-02 Piramal Entpr Ltd Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
KR101569522B1 (ko) 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EA201592126A1 (ru) 2013-05-17 2016-05-31 Ф. Хоффманн-Ля Рош Аг 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
HRP20181863T1 (hr) 2013-05-17 2018-12-28 Janssen Sciences Ireland Uc Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
JO3583B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN104870429B (zh) 2013-05-22 2017-05-03 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
TR201806822T4 (tr) 2013-06-14 2018-06-21 Gilead Calistoga Llc Fosfatidilinositol 3-kinaz inhibitörleri.
CN104507921B (zh) 2013-07-02 2017-02-22 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
US20160145304A1 (en) 2013-07-12 2016-05-26 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
CN104341407A (zh) 2013-07-24 2015-02-11 黄传满 喹唑啉类化合物及其制备方法和用途
NO3024819T3 (es) 2013-07-25 2018-07-21
CN105143181B (zh) 2013-07-26 2017-12-26 四川海思科制药有限公司 三元并环羧酸类衍生物、其制备方法及其在医药上的应用
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
JP6397410B2 (ja) 2013-08-09 2018-09-26 武田薬品工業株式会社 芳香環化合物
CN104418801B (zh) 2013-08-19 2016-10-05 上海润诺生物科技有限公司 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
EP3036237A4 (en) * 2013-08-23 2017-01-25 Fujian Haixi Pharmaceuticals Co. Ltd Carboxylic acid compounds in treatment of diabetes mellitus
CA2922567A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
WO2015028960A1 (en) 2013-08-28 2015-03-05 Piramal Enterprises Limited Substituted heterocyclic derivatives as gpr agonists and uses thereof
WO2015032328A1 (zh) 2013-09-03 2015-03-12 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
ES2642074T3 (es) * 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Compuestos útiles como inmunomoduladores
CN105814028B (zh) 2013-09-06 2018-02-16 奥瑞基尼探索技术有限公司 作为免疫调节剂的1，2，4‑*二唑衍生物
PL3043865T3 (pl) 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
JP6533778B2 (ja) 2013-09-26 2019-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ４０アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CN104592211B (zh) 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
HK1223094A1 (zh) 2013-11-14 2017-07-21 Novira Therapeutics Inc. 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN105916500A (zh) 2013-11-27 2016-08-31 欧洲筛选有限公司 用于治疗炎性疾病的化合物、药物组合物和方法
JP6441928B2 (ja) 2013-11-28 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシフェニルシクロプロパンカルボン酸
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
TW201609722A (zh) 2013-12-13 2016-03-16 美國禮來大藥廠 新穎三唑并吡啶化合物
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
CN105899509B (zh) 2014-01-10 2018-01-02 伊莱利利公司 异丙基三唑并吡啶化合物
KR20160095117A (ko) 2014-01-10 2016-08-10 일라이 릴리 앤드 캄파니 페닐-트리아졸로-피리딘 화합물
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP2017504633A (ja) 2014-01-30 2017-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
ES2714110T3 (es) 2014-03-07 2019-05-27 Hoffmann La Roche Heteroarildihidropirimidinas 6-fusionadas novedosas para el tratamiento y profilaxis de la infección por el virus de la hepatitis B
JP2017507983A (ja) 2014-03-18 2017-03-23 アイティーオス セラペウティクス 新規な３−インドール置換誘導体、医薬組成物、および使用方法
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
ES2823825T3 (es) 2014-04-04 2021-05-10 Iomet Pharma Ltd Derivados de indol para su uso en medicina
AU2015243849B2 (en) 2014-04-10 2020-12-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
KR20170002543A (ko) 2014-05-07 2017-01-06 브리스톨-마이어스 스큅 컴퍼니 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제
WO2015171757A1 (en) 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
TR201809633T4 (tr) 2014-05-07 2018-07-23 Bristol Myers Squibb Co Diyabet gibi hastalıkların tedavisine yönelik pirolidin GPR40 modülatörleri.
CA2948080A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
NZ726052A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
JP6678599B2 (ja) 2014-06-13 2020-04-08 ユニバーシティー オブ ロチェスター 小分子排出ポンプ阻害剤
GB201411239D0 (en) 2014-06-25 2014-08-06 Takeda Pharmaceutical Novel compounds
GB201411236D0 (en) 2014-06-25 2014-08-06 Takeda Pharmaceutical Novel compounds
TW201613878A (en) 2014-07-09 2016-04-16 Janssen Pharmaceutica Nv Pyrazine GPR40 agonists for the treatment of type II diabetes
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
WO2016018729A1 (en) 2014-07-29 2016-02-04 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
CN106573898B (zh) 2014-08-14 2018-11-09 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
WO2016032120A1 (ko) 2014-08-27 2016-03-03 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
EA201790154A1 (ru) 2014-08-27 2017-08-31 Джилид Сайэнс, Инк. Соединения и способы для ингибирования гистоновых деметилаз
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
JP2016053633A (ja) 2014-09-03 2016-04-14 日東電工株式会社 偏光板の製造方法
TN2017000084A1 (en) 2014-09-11 2018-07-04 Bristol Myers Squibb Co Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
UY35733A (es) 2014-09-12 2016-04-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c.
TW201625527A (zh) 2014-09-19 2016-07-16 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 苯并雜環化合物及其應用
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
WO2016057924A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
EP3206691B1 (en) 2014-10-14 2018-09-19 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CA2960944C (en) 2014-10-17 2019-09-10 Hyundai Pharm Co., Ltd. Use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivatives in combination with a secondary active ingredient for the treatment of metabolic diseases
AR102426A1 (es) 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
KR101857146B1 (ko) 2014-10-28 2018-05-11 삼성에스디아이 주식회사 유기 광전자 소자 및 표시 장치
CA2965741C (en) 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016090190A1 (en) 2014-12-03 2016-06-09 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
JP2017537929A (ja) 2014-12-05 2017-12-21 ジェネンテック， インコーポレイテッド Ｐｄ−１軸アンタゴニスト及びｈｐｋ１アンタゴニストを用いたがん治療のための方法及び組成物
EP3234144B1 (en) 2014-12-15 2020-08-26 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
CA2973185C (en) 2015-01-08 2021-02-16 Advinus Therapeutics Limited Bridgehead nitrogen bicyclic inhibitors/modulators of retinoic acid-related orphan receptor gamma (ror.gamma.)
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
HK1249030A1 (zh) 2015-02-06 2018-10-26 Unity Biotechnology, Inc. 化合物及在治疗衰老相关病症中的用途
EP3256471B1 (en) 2015-02-11 2018-12-12 F. Hoffmann-La Roche AG Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
DK3097102T3 (en) 2015-03-04 2018-01-22 Gilead Sciences Inc TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS
JP2018507894A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての３−置換−１，２，４−オキサジアゾールおよびチアジアゾール化合物
WO2016142835A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited Therapeutic cyclic compounds as immunomodulators
AU2016230767A1 (en) 2015-03-10 2017-09-07 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
JP2018507885A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
CN104876912B (zh) 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
CN108026098B (zh) 2015-04-12 2019-09-03 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
HK1248235A1 (zh) 2015-05-15 2018-10-12 吉利德科学公司 具有作为吲哚胺2，3-二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物
MA43344A (fr) 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
ES2810700T3 (es) 2015-05-29 2021-03-09 Hoffmann La Roche Metilación del promotor de PD-L1 en cáncer
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
CN107709336B (zh) 2015-06-12 2021-06-22 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
EP3322420B1 (en) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
EP3331860B1 (en) 2015-08-07 2019-07-17 Boehringer Ingelheim International GmbH Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US9920040B2 (en) 2015-08-12 2018-03-20 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
WO2017027312A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
US9908873B2 (en) 2015-08-12 2018-03-06 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
WO2017031392A1 (en) 2015-08-20 2017-02-23 University Of Florida Research Foundation, Incorporated Lipid compounds for treatment of obesity, hypertension and metabolic syndrome
JP2018526405A (ja) 2015-09-09 2018-09-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用
HK1250517A1 (zh) 2015-09-17 2018-12-21 Novartis Ag 增强功效的car t细胞疗法
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180353483A1 (en) 2015-11-04 2018-12-13 Incyte Corporation Pharmaceutical compositions and methods for indoleamine, 2, 3-dioxygenase inhibition and indications therefor
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
KR20180093990A (ko) 2015-12-07 2018-08-22 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Pd-1 시그널 저해제의 병용 요법
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
CN115010712B (zh) 2015-12-24 2025-07-25 基因泰克公司 Tdo2抑制剂
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
US11583528B2 (en) 2016-02-17 2023-02-21 Children's Medical Center Corporation FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US9798514B2 (en) 2016-03-09 2017-10-24 Spotify Ab System and method for color beat display in a media content environment
EP3432878A1 (de) 2016-03-23 2019-01-30 Symrise AG Homovanillinsäure-ester zum reduzieren oder inhibieren der fettsäureaufnahme im dünndarm
WO2017172505A1 (en) 2016-03-29 2017-10-05 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2017180457A1 (en) 2016-04-11 2017-10-19 Janssen Pharmaceutica Nv Gpr40 agonists in anti-diabetic drug combinations
WO2017180571A1 (en) 2016-04-11 2017-10-19 Janssen Pharmaceutica Nv Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
US20190062272A1 (en) 2016-04-13 2019-02-28 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
RU2735541C2 (ru) 2016-05-23 2020-11-03 Инститьют Оф Материя Медика, Чайниз Экедеми Оф Медикал Сайенсез Простое эфирное производное никотинилового спирта, получение и фармацевтическая композиция и применения
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
WO2017202744A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
KR102491992B1 (ko) 2016-07-08 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 1,3-디히드록시-페닐 유도체
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US10872055B2 (en) 2016-08-02 2020-12-22 Qualcomm Incorporated Triple-data-rate technique for a synchronous link
JP2019530732A (ja) * 2016-08-03 2019-10-24 アライジング・インターナショナル・インコーポレイテッドＡｒｉｓｉｎｇ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｉｎｃ． 免疫モジュレータとして有用な対称または半対称化合物
EP3281937A1 (en) 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
US10563620B2 (en) 2016-08-12 2020-02-18 Rolls-Royce North American Technologies Inc. Expandable exhaust cone
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10734026B2 (en) 2016-09-01 2020-08-04 Facebook, Inc. Systems and methods for dynamically providing video content based on declarative instructions
WO2018045142A1 (en) * 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018053302A1 (en) 2016-09-19 2018-03-22 Ensemble Therapeutics Corporation Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
JP7050797B2 (ja) 2016-10-25 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用
WO2018081047A1 (en) 2016-10-25 2018-05-03 Janssen Pharmaceutica Nv Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
WO2018095877A1 (en) 2016-11-28 2018-05-31 Boehringer Ingelheim International Gmbh Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
KR102007633B1 (ko) 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
JP7106572B2 (ja) 2016-12-20 2022-07-26 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤として有用な化合物
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
WO2018119224A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3564237A4 (en) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN110312714B (zh) 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
JP7023969B2 (ja) 2017-01-26 2022-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
US10253004B2 (en) 2017-01-26 2019-04-09 Boehringer Ingelheim International Gmbh Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
JP7132937B2 (ja) 2017-03-15 2022-09-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１の阻害剤としてのアザインドール
GB201704714D0 (en) 2017-03-24 2017-05-10 Caldan Therapeutics Ltd Pharmaceutical compounds
JP7150745B2 (ja) 2017-03-27 2022-10-11 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤としての置換イソキノリン誘導体
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
BR112019018093A2 (pt) 2017-03-30 2020-06-16 F. Hoffmann-La Roche Ag Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
WO2018181847A1 (ja) 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
WO2019008156A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
MA49701A (fr) 2017-07-28 2020-06-03 Chemocentryx Inc Composés immunomodulateurs
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
CN109400522B (zh) 2017-08-18 2023-04-28 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
WO2019074241A1 (ko) 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
EP3733659B1 (en) 2017-12-29 2023-12-20 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
KR102708681B1 (ko) * 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
GB201803736D0 (en) 2018-03-08 2018-04-25 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2019174533A1 (zh) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
CA3093851A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
CN111936475B (zh) 2018-04-03 2024-05-10 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
CN112424185B (zh) 2018-07-13 2024-05-17 广州丹康医药生物有限公司 含苯环的化合物、其制备方法及应用
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors

Also Published As

Publication number Publication date
EP3752501A1 (en) 2020-12-23
US10710986B2 (en) 2020-07-14
AU2021204222A1 (en) 2021-07-29
JP2022037169A (ja) 2022-03-08
JP7062792B2 (ja) 2022-05-06
BR102019002873A2 (pt) 2019-09-10
ES2949664T3 (es) 2023-10-02
UA126458C2 (uk) 2022-10-05
TW202116759A (zh) 2021-05-01
CN111712494A (zh) 2020-09-25
EP3752501B1 (en) 2023-04-19
KR20230147740A (ko) 2023-10-23
IL300572A (en) 2023-04-01
IL276246B1 (en) 2023-03-01
US20190270727A1 (en) 2019-09-05
PH12020551244A1 (en) 2021-05-17
AU2019222644A1 (en) 2020-09-03
CA3091015C (en) 2023-02-21
DOP2020000154A (es) 2020-09-15
IL276246B2 (en) 2023-07-01
KR20220133305A (ko) 2022-10-04
KR102586510B1 (ko) 2023-10-12
US20230212155A1 (en) 2023-07-06
EP4227302A1 (en) 2023-08-16
SI3752501T1 (sl) 2023-08-31
PL3752501T3 (pl) 2023-08-21
TWI796596B (zh) 2023-03-21
AU2023202364A1 (en) 2023-05-25
US20210053946A1 (en) 2021-02-25
MY196582A (en) 2023-04-19
US12338233B2 (en) 2025-06-24
AU2019222644B2 (en) 2021-04-01
AU2021204222B2 (en) 2023-02-16
MX2020008404A (es) 2020-09-25
CO2020009861A2 (es) 2020-08-21
US20250270195A1 (en) 2025-08-28
TWI707849B (zh) 2020-10-21
PT3752501T (pt) 2023-07-12
KR102445054B1 (ko) 2022-09-22
PE20210640A1 (es) 2021-03-23
CL2020002082A1 (es) 2020-12-11
KR102708681B1 (ko) 2024-09-26
KR20200121323A (ko) 2020-10-23
US11555029B2 (en) 2023-01-17
SG11202007646UA (en) 2020-09-29
CN118084940A (zh) 2024-05-28
JP2021513561A (ja) 2021-05-27
MX2022014548A (es) 2023-01-11
WO2019160882A1 (en) 2019-08-22
IL276246A (en) 2020-09-30
TW201942117A (zh) 2019-11-01
CA3091015A1 (en) 2019-08-22
BR112020016466A2 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
CR20210013A (es) Inhibidores de pd-1/pd-l1
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
EP4600247A3 (en) Pd-1/pd-l1 inhibitors
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
EP4616910A3 (en) Pcna inhibitors
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
AU2020378127A8 (en) Compounds as CD73 inhibitors
MX2020011002A (es) Combinacion que comprende inhibidor de hdac, inhibidor de lag-3 y un inhibidor de pd-1 o inhibidor de pd-l1 para el tratamiento del cancer.
EA202091694A1 (ru) Ингибиторы pd-1/pd-l1
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof
PH12021552389A1 (en) Quinoline derivatives and their use for the treatment of cancer
MX2021007967A (es) Inhibidores de síntesis de leucotrienos.
EA202193121A1 (ru) Лечение рака
EA202092733A1 (ru) Ингибиторы pd-1/pd-l1
EA201992045A1 (ru) Ингибиторы pd-1/pd-l1
JOP20180038A1 (ar) مثبطات pd-1/pd-l1